key: cord-0881650-fgdmes2t
authors: Levin, Zachary; Chang, Jessica; Karaca-Mandic, Pinar; Duarte-García, Alí; Jeffery, Molly Moore
title: Characteristics of Hydroxychloroquine Dispensing in the United States, January to May 2020
date: 2021-10-26
journal: J Gen Intern Med
DOI: 10.1007/s11606-021-07175-9
sha: 3ff2c6aa770c6189dee17483eb1c2eef352baae2
doc_id: 881650
cord_uid: fgdmes2t

nan

To determine whether the new fills were associated with a clinician visit (including telemedicine), we looked for any evaluation and management code, irrespective of the diagnosis code, in the 2 weeks prior to the fill.

We identified 66,523 enrollees with 134,417 HCQ fills (Table 1 ) during the study period; 28.8% of these enrollees had no previous use of HCQ. Our sample was predominantly female, and among indicated users, the most common diagnosis was RA. Nearly 13,000 new fillers (67.2%) did not have indication; among previous fillers, 15.1% had no indication. The sample of new fillers without an indication was unlike both new fillers with an indication and previous fillers, with fewer women and Medicare Advantage enrollees. These findings were robust to a sensitivity analysis using a 365-day look-back period (among those with 365 days prior enrollment, 27.9% of fillers had no previous HCQ use; 67.1% of new and 15.0% of previous fillers had no indication). COVID-19 diagnosis status was examined independently of standard indications for HCQ. A suspected or confirmed COVID-19 diagnoses was found in 11.0% of non-indicated fills and 2.5% of otherwise indicated fills.

The rate of HCQ fills per 1000 enrollees increased substantially in mid-March among both new and previous HCQ fillers (Fig. 1 ). The percent of HCQ fills associated with a recent clinician's visit also experienced significant volatility coinciding with COVID-19. In February, 41.5% of new HCQ fillers and 73.5% of prior HCQ fillers had a clinician visit in the 2 weeks prior to dispensing. During the first 2 weeks of March, 40.1% of prior fillers had a clinician visit, dropping to 35.9% during the following 2 weeks. For new fillers, however, this percentage dropped dramatically from 71.3 to 31.3%.

Our results provide a picture of HCQ prescribing that is consistent with concerning use of this medication for COVID-19, as most new fillers had no documented HCQ indication and did not have a clinician's visit 2 weeks before the dispensing. Our results suggest that HCQ may have been initiated without full examination and screening for potential interactions or side effects. 4 We also observed a spike in fills by people with a history of HCQ use, consistent with fear of a drug shortage caused by COVID-19-associated demand for HCQ. 5 Our study is limited by our inability to observe whether HCQ supply may have limited the number of fills during this period.

While the mid-March spike in HCQ was concerning, the number of new fillers dropped quickly by early May, suggesting a response to further information on the lack of benefits from (and potential risks of) HCQ. 6 Our results provide evidence of strong uptake of medication usage during times of uncertainty. 

Misguided Use of Hydroxychloroquine for COVID-19

OptumLabs and OptumLabs Data Warehouse (OLDW) Descriptions and Citation

Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment -United States

Potential Shortages of Hydroxychloroquine for Patients with Lupus During the Coronavirus Disease

Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv